PPT-Genomic Prostate Cancer Testing for Olaparib

Laura YarramSmith Solid Tumour Lead SWGLH July 2023 httpswwwnbtnhsuksouthwestgenomiclaboratoryhub Part of a Genomic Medicine Service Bristol Clinical Genetics Peninsula Clinical Genetics. Prostate Cancer Screening and Treatment. Mr Stephen Lindsay. Urological Surgeon. Bendigo. www.bendigourology.com. Prostate Cancer Risk Assessment. Prostate Cancer. Since the early 1990’s, Prostate Cancer has been the most commonly diagnosed cancer in Australian men (. This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a . Environmental Scan. April 2017. Background. The Canadian Partnership Against Cancer collects information annually on . national, provincial . and territorial . prostate . cancer screening guidelines, strategies, and activities. . proceedings from the live CME event and may include . the use of trade names and other raw, unedited content. . Module 1: PARP Inhibition as a Therapeutic Strategy — Ovarian Cancer (OC) at the Vanguard . Prostate cancer is the most common cancer in males Most men develop prostate cancer by chance or as a result of risk factors that occur over the course ofa lifetime However approximately 10percentof m The second most common cancer diagnosed in men. The incidence increase with age very rare before age of 40, more in western countries particularly Scandinavian countries (low light exposure), and black men are at greatest risk. Asymptomatic pt. General concern. +/- . FHx. CHAPS / IPSS / failed venesection / ?informed / ?. E. uropean guidance. Symptomatic pts (LUTS, ED, vis haem; LBP/. wt. loss). PSA (prostate-specific antigen) is a serine protease enzyme produced by prostate epithelial cells (both normal and malignant).. Rob Finch, MS, CGC. Certified Genetic Counselor. Medical Science Liaison. Myriad Genetic Laboratories. Somatic vs. Germline Mutation . Tumor Testing vs. Germline Testing . Tumor Biopsy . Blood Test . Prostate cancer is the most common cancer in males . M ost men develop prostate cancer by chance or as a result of risk factors that occur over the course of a lifetime. However, approximately 10 pe –. To treat . or not to treat. Dr Oliver Klein – Medical Oncologist. Prostate Cancer. |. . Epidemiology- Australia. Most common cancers 2012 . Cancer related deaths 2010 . Australian Institute of Health and Welfare. Latest developments. . Prof.. . Neeraj Agarwal, MD. Director, Genitourinary Oncology Program, . Huntsman Cancer Institute, University of Utah, USA. MARCH 2022. PARPi. , poly-ADP ribose polymerase inhibitors. Foundation Medicine. ctDNA. is good information for somatic mutations in . mCRPC. when biopsy is not possible. lots of other data on the importance of CTCs as predictive. 93% concordance for BRCA1/2 for tissue and liquid biopsy – . Dr Marie-Pier St-Laurent, MD, FRCSC. Urologic-Oncology fellow, UBC. Research scientist, Vancouver Prostate Centre. Honorarium: Bayer, PCSC. As a urologist, I am biased towards prostate cancer screening.. Louise Medley. Consultant Medical Oncologist & Cancer Clinical Lead SW GLH. SWAG OG CAG March 24. th. 2023. WHY?. Prevention. Early Diagnosis. Neo-adjuvant . Adjuvant . Palliative. Living with Cancer .